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the  GK gene. A deletion extending to  IL1RAPL1 was con-
firmed in both patients showing MR. Thus, a good geno-
type-phenotype correlation was confirmed.  Conclusions: 
 Multiplex ligation-dependent probe amplification analysis is 
a valuable tool to detect  NR0B1 and contiguous gene dele-
tions in patients with AHC. It is especially helpful for  IL1RAPL1 
 deletion detection as no clinical markers for MR are available. 
Furthermore, multiplex ligation-dependent probe amplifi-
cation has the advantage to identify female carriers that, de-
pending on the deletion extension, have a high risk of giving 
birth to children with MR, AHC, glycerol kinase deficiency 
and Duchenne muscular dystrophy. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 X-linked congenital adrenal hypoplasia (AHC) is a
developmental disorder of the human adrenal cortex.
Although rare, it is the most common form of primary 
 Key Words 
 Adrenal hypoplasia congenita    NR0B1   Multiplex
ligation-dependent probe amplification   Contiguous
gene deletion 
 Abstract 
 Background/Aim:  X-linked adrenal hypoplasia congenita 
(AHC) is a rare disorder characterized by primary adrenal in-
sufficiency and hypogonadic hypogonadism. It is caused by 
deletions or point mutations of the  NR0B1  gene, on Xp21. 
AHC can be associated with glycerol kinase deficiency, Du-
chenne muscular dystrophy and mental retardation (MR), as 
part of a contiguous gene deletion syndrome. A synthetic 
probe set for multiplex ligation-dependent probe amplifica-
tion analysis was developed to confirm and characterize 
 NR0B1 deletions in patients with AHC and to correlate their 
genotypes with their divergent phenotypes.  Results:  In 2 
patients, isolated AHC was confirmed, while a patient at risk 
for metabolic crisis was revealed as the deletion extends to 
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adrenal hypoplasia reported  [1] . It is characterized by
primary adrenal insufficiency (AI), hypogonadic hypo-
gonadism (HH) and a defect in spermatogenesis. AI has 
an apparent bimodal manifestation onset, generally pre-
sents with severe salt-losing adrenal crisis within the first 
2 months of life or it can manifest in a more insidious 
manner with adrenal failure during childhood. HH man-
ifests during adolescence as absent or arrested puberty 
due to hypothalamic and pituitary defects.
 X-linked AHC is caused by deletions or point muta-
tions of the  NR0B1 (DAX1) gene, located on Xp21.2  [2, 3] . 
 NR0B1 encodes for an orphan nuclear receptor that is ex-
pressed in the developing adrenal gland, the gonads, the 
hypothalamus and the pituitary gland  [4] . Duplications 
of the  NR0B1 locus are responsible for XY gonadal dys-
genesis  [5, 6] .
 Deletions can affect the  NR0B1  gene alone or extend 
to the neighboring genes; thus, AHC can be detected as 
part of a contiguous gene syndrome (CGS) together with 
glycerol kinase deficiency (GKD), Duchenne muscular 
dystrophy (DMD) and mental retardation (MR). It has 
been calculated that isolated and contiguous  NR0B1 gene 
deletions account for 22 and 5% of all  NR0B1 mutations, 
respectively  [7] .
 GKD is caused by mutations or deletions of the gene 
for glycerol kinase  (GK) , an enzyme involved in the glyc-
erol metabolism. GKD, even in the isolated form, presents 
with variable phenotypes, and even within the same fam-
ily, these range from asymptomatic hyperglycerolemia to 
severe and life-threatening metabolic crisis and/or psy-
chomotor retardation  [8, 9] . DMD, together with Becker 
muscular dystrophy, is a neuromuscular disease charac-
terized by progressive muscular weakness and degenera-
tion of skeletal muscle and is caused by mutations of the 
 DMD gene; at least 20% of the patients also show mental 
impairment  [10] .
 MR associated with AHC cannot be explained with 
GKD or DMD in every case. Deletions extending to the 
 IL1RAPL1 gene have been shown to be responsible for 
MR in several cases  [11–13] . In fact, partial  IL1RAPL1 de-
letions and nonsense mutations have been described as 
cause of nonspecific X-linked MR  [11, 14, 15] .
 The aim of this study was to develop a multiplex liga-
tion-dependent probe amplification (MLPA) synthetic 
probe set to confirm and characterize  NR0B1 deletions 
( fig. 1 ) in patients with AHC and to correlate their geno-
types to the variant phenotypes.
 Patients and Methods 
 Patients 
 Five male patients suffering from AHC and their mothers, if 
available, have been included in the study. All patients manifested 
with severe salt loss during infancy (mean age at manifestation 3.4 
weeks, range 2–5). Aldosterone concentrations in plasma were in 
the lower normal range, but inadequately low for the degree of hy-
ponatremia and the elevated levels of plasma renin activity. Adre-
nal glucocorticoid biosynthesis was normal or in the lower range; 
however, adrenocorticotropin hormone was highly elevated re-
vealing an imminent addisonian crisis. Levels of 17-hydroxypro-
gesterone were within or below the normal range for respective 
age. All infants showed normal male external genitalia with slight 
hyperpigmentation. In 2 out of the 5 patients, testosterone was 
measured (range 1.2–6.9 nmol/l), revealing levels within the nor-
mal range for the minipuberty reflecting testicular androgen bio-
synthesis  [16] . All patients were treated with fludrocortisone by 
the time of the manifestation of mineralocorticoid deficiency and 
with hydrocortisone for a diagnosis of glucocorticoid deficiency. 
An  NR0B1  deletion was detected previously with polymerase 
chain reaction (PCR) techniques as cause for the disease  [2] .
 Patient 1 and patient 2 are adults and suffer from AI and per-
manent HH. Testosterone replacement therapy was initiated dur-
ing adolescence. Both patients reached a normal final height for 
the family and population standards. No mental deficits are re-
ported. Patient 3 is a 13.8-year-old adolescent suffering from AI. 
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 Fig. 1. DAX1-del probe set. MLPA trace results for the DAX1-del 
probe set. Peaks corresponding to control probes are labeled ( * ) 
and their size in bp is reported along the x-axis at the bottom of 
the figure. Arrows indicate deleted probes. 
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patient suffers from DMD showing the typical characteristics 
with decreasing muscle strength over time. Presently, he has sig-
nificantly reduced movement abilities and is wheelchair bound. 
Laboratory investigation reveals elevated levels for creatine ki-
nase 5,630 U/l (normal value  ! 247) and aspartate aminotransfer-
ase (75 U/l, normal range 10–50). Triglyceride levels are continu-
ously increased (450 mg/dl, normal value  ! 200). A karyotype 
analysis revealed a normal male 46,XY status without noticeable 
deletions within the X chromosome. Of note is a short stature 
(128.5 cm, –4.0 SDS), aggravated by the lack of puberty, and obe-
sity (body mass index 27.1 + 2.4 SDS). The patient showed a speech 
and psychomotor delay starting in infancy. He has persistent ver-
bal deficits as well as severe MR. Furthermore, he suffers from 
generalized seizures and is currently treated with lamotrigine.
 Patient 4 is currently 6.7 years old and shows AI combined 
with an attention deficit disorder and verbal deficits. He has a his-
tory of speech and psychomotor delay starting in infancy. Labora-
tory results for creatine kinase, aspartate aminotransferase and 
triglyceride levels are within the normal range for age and sex.
 Patient 5 is a 1.7-year-old infant with apparent isolated AI. A 
developmental deficit or metabolic crisis was not recorded so far. 
Additional laboratory investigations revealed elevated levels of 
urinary glycerol (1,680 mmol/mol creatine, control range unde-
tectable).
 Multiplex Ligation-Dependent Probe Amplification  
 Synthetic probes for MLPA were designed as previously de-
scribed  [6, 17] . Some probes were already available at our labora-
tory from previous studies  [6, 18] , others were newly designed. 
The complete DAX1-del probe set ( table 1 ) was tested in normal 
controls. The EK1 reagent kit (MRC Holland, Amsterdam, The 
Netherlands) was used for the MLPA reaction, according to the 
manufacturer’s recommendation, starting from 100 ng of ge-
nomic DNA for each sample. The PCR products were separated 
by capillary electrophoresis on an ABI 3100 genetic analyzer 
(Applied Biosystems). Trace data were analyzed using the Gene-
Mapper version 3.7 software, and the integrated peak heights 
and areas were exported to an Excel spreadsheet (Microsoft) for 
further calculations. For each sample, the peak height/area was 
first normalized to the average peak height/area of the three con-
trol probes, followed by normalization to the average peak 
height/area of the control samples included in the run. The anal-
Table 1.  DAX1-del probe set
Probe name Size
bp






GABRA4a 84 CAGCCTGTTGTCATAACCATCG AGCAAACTGTCCAGGATGCG 0.02 0.02 1.01
RELN2b 87 CAGCATTACGGAATGAAGGTCA CCACAAGAAGTGGCTTCACAACC 0.05 0.04 0.99
CXorf21 90 CCAGCCACCTGCTCATTATAAGAG GCACAACTCCAGTGGATGTCATTC 0.06 0.05 0.60
GK 96 CACTATATGTAGGTTATCTCTTCGGTGACA TACACTGCAATTTGAGAGGGCTGG 0.06 0.06 0.54
GK5UP 99 CCTGTCCGAGCGTTCGGCTCTTTTGCGT TTGCTGATTGGCCAGCCCAGGTGACAGCG 0.02 0.06 0.56
DAX1ex1 102 GCAGCCTCAGCGGGCCTGTTGAAGACG-
CTG
CGCTTCGTCAAGTACTTGCCCTGCTTCCAG 0.02 0.03 0.55




















































a  Pilot probe. b Control probes that hybridize on autosomal chromosomes. c The 5 half-probes are preceded by the universal tag sequence 
GGGTTCCCTAAGGGTTGGA; the 3 half-probes are followed by the universal tag sequence TCTAGATTGGATCTTGCTGGCAC and are phosphory-
lated at the 5 end. d Median of 4 male controls normalized using female controls.
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ysis was considered acceptable if the ratio for the internal control 
was between 0.8 and 1.2. Threshold values for deletions and du-
plications were set at 0.75 and 1.25, respectively. When analyzing 
male patients for deletion, a visual inspection is sufficient as the 
probes within a deletion on the X chromosome result as missing 
( fig. 1 ).
 Copy Number Determination with Cyto2.7M 
 For microarray analysis, the Cyto2.7M array platform was 
used (Affymetrix, Santa Clara, Calif., USA). Experimental proce-
dures were performed according to the protocols provided by the 
manufacturer (Affymetrix; http://www.affymetrix.com). Micro-
arrays were washed and stained with the Fluidics Station 450 (Af-
fymetrix) and scanned with the GeneChip Scanner 3000 (Af-
fymetrix). Copy number analyses of the Cyto2.7M array was per-
formed using the Chromosome Analysis Suite Software (version 
1.0.1, annotation file 30.0; Affymetrix). Mapping was done ac-
cording to NCBI genome build 36.
 Results 
 Multiplex Ligation-Dependent Probe Amplification  
 The DAX1-del probe set ( table 1 ) was tested in 6 female 
and 4 male controls. SD was calculated for the 6 female 
controls and all probes had a SD  ! 10%, thus proving to 
be reliable and sufficiently consistent ( table  1 ). For the 
probes on the X chromosome, the median ratio value in 
the male controls, when calculated against the average of 
the female control values, ranged from 0.53 to 0.60, being 
consistent with a hemizygosity value ( table 1 ).
 A summary of the results is presented in  figure 2 . Pa-
tient 1 showed missing peaks corresponding to the region 
covered by probe MAGEB1 thorough probe CXorf21. 
Therefore, he carries a deletion extending from  MAGEB1, 
 including  NR0B1, to the  CXorf21 gene. The deletion was 
maternally inherited. Patient 2 carries a deletion of only 
the first exon of  NR0B1 which in fact could not be ampli-
fied by PCR; exon 2 is still present. Also in this case, the 
mutation was maternally inherited. All probes on Xp21 
were absent in patient 3, so the extension of the deletion 
was not established but extends to at least the last exon
of  IL1RAPL1, telomerically, and to the last exon of the 
DMD gene, centromerically. A maternal sample was not 
available for this patient. A deletion affecting the entire 
 NR0B1 extending to the  IL1RAPL1 gene was detected in 
patient 4 and his mother; both probes on the  IL1RAPL1 
 were missing, thus the extension of the telomeric break-
point could not be determined. A deletion from IGS12 to 
MAP3K7IP3ex12  probes, including the  NR0B1  and  GK 
genes, was detected in patient 5. Again, the deletion was 
inherited from the mother.
 Microarray Analysis 
 To unravel the extension of the deletion and the cor-
responding breakpoints in index patients 3 and 4, we per-
formed a microarray analysis with the Cyto2.7M plat-
form. In index patient 3, we detected an approximately 
2,204-kb deletion on chromosome Xp21.3p21.3 with the 
Fig. 2. DAX1-del probe set and  NR0B1 de-
letion representation. Representation from 
the UCSC genome browser (March 2006, 
NCBI36, hg18) of the  NR0B1 locus on 
Xp21. Probes included in the DAX1-del set 
are represented as vertical red lines. Green 
horizontal lines represent the minimal de-
leted regions. Pt = Patient.
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most telomeric deleted probe starting at chrX:29,065,611 
bp and the most centromeric deleted probe ending at 
chrX:31,270,355 bp (arrXp21.3.p21.3)(29,061,807x1,29,
065,611x0-31,270,355x0,31,271,211x1). For index patient 
4, we detected an approximately 2,348-kb-sized deletion 
on chromosome Xp21.3p21.2, with the most telomeric 
deleted probe starting at chrX:27,988,531 bp and the most 
centromeric deleted probe ending at chrX:30,427,408 bp 
(arrXp21.3p21.2)(27,985,052x1,27,988,531x0-30,427,
408x0,30,428,437x1). His mother is heterozygous for this 
deletion ( fig. 3 ).
 Discussion 
 The manifestation of AI in the context of AHC may be 
the first symptom of a CGS. While AI is usually a symp-
tom of early infancy, the additional features seen in the 
CGS like DMD, GKD and MR are most often detected 
with major delay. In order to accelerate the diagnostic 
workup and to allow genetic counseling of the affected 
families, the DAX1-del probe set was developed with the 
aim to characterize the extension of deletions within the 






 Fig. 3. Results of microarray analysis with the Cyto2.7M platform. Microarray results for the index patient (Pt.) 
4, the mother of patient 4, and patient 3. The figure includes a map of the deleted chromosomal region with a 
close-up view of the genes lying within the deleted region (parts of the figure were composed with the UCSC 
genome browser). The position of  NR0B1  (DAX1) is indicated by the red arrow. 
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 DMD are responsible for the additional symptoms in case 
of AHC due to a CGS.
 Probes were tactically designed within the two exons 
of the  NR0B1 gene in order to detect single-exon as well 
as entire gene deletions; probe GK5UP is located 65 bp 
upstream the  GK gene (according to USCS genome 
browser, March 2006 NCBI36/hg18) in order to identify 
deletions extending very near but not including the  GK 
gene; probe GK is located instead within the last  GK in-
tron; probes DMD and DMD3UTR were placed within 
the last coding exon and at the very end of the 3  UTR of 
the DMD genes, respectively, in order to detect the most 
possible terminal deletions. For  IL1RAPL1, probes were 
placed within the last exon (IL1RAPL1) and 5.5 kb down-
stream the gene (IL1RAPL1-3DS), again in order to iden-
tify deletions that extend to the very end of the gene. 
Probes within intergenic regions (IGS4 and IGS12) and 
other genes (MAGEB1, CXorf21 and MAP3K7IP3ex12) 
were included to confirm the deletion results for the 
probes within the genes of interest.
 With our probe set, we analyzed 5 patients with AHC 
due to  NR0B1 deletions, previously detected by PCR, and 
evaluated the correlation of the phenotype with the ex-
tension of deletion to the neighboring genes. In patient 1, 
in addition to  NR0B1, the deletion also affects  MAGEB1 
and  CXorf21 but does not reach either  IL1RAPL1  or  GK, 
thus confirming the isolated AHC phenotype. In patient 
2, a deletion affecting exon 1 but not exon 2 was suspect-
ed by PCR analysis and confirmed by MLPA. This is the 
first report of a deletion affecting only the first exon of 
 NR0B1.  A complex rearrangement consisting of a 2.2-kb 
deletion affecting exon 2 together with a 27-bp insertion 
has also been described  [19] , indicating the importance 
of having probes within both  NR0B1 exons. Moreover, 
MLPA analysis allowed the exclusion of a deletion ex-
tending to the upstream region of the  GK gene. Thus, a 
possible metabolic crisis is excluded and the isolated 
AHC phenotype confirmed. In patient 3, all probes were 
deleted, confirming the clinical and laboratory pheno-
type of AHC and HH due to  NR0B 1 deletion, GKD and 
DMD. With the Cyto2.7M microarray platform, we con-
firmed the results from the MLPA analysis. Moreover, we 
were able to map the deleted region and the correspond-
ing breakpoints. The deleted region contains the genes 
 ILRAPL1, MAGEB2, CXorf21, GK, MAP3K7IP3, FTHL17 
and  DMD. The seizures may be a consequence of GKD. 
Furthermore, the deletion of  IL1RAPL1 may aggravate 
the mental phenotype. Short stature has been described 
in a family with a deletion of  IL1RAPL1  [14] .
 The  NR0B1 deletion in patient 4 extends telomerically 
to  IL1RAPL1, explaining his MR phenotype. The  GK gene 
on the other hand is not affected, and the development of 
a metabolic crisis can be excluded. Once more, MLPA re-
sults were reproducible with the microarray analysis. 
Mapping of the deletion confirmed that  GK is not lying 
in the deleted region. The deletion in patient 5 also affects 
the  GK gene, but not  IL1RAPL1. In fact, a MR phenotype 
has not yet been shown by the patient; however, he is at 
risk of a metabolic crisis and a consequent mental pheno-
type due to GKD.
 We conclude that with our MLPA analysis we con-
firmed a phenotype/genotype correlation in patients with 
AHC due to CGS, where all patients with MR carry a de-
letion affecting also the  IL1RAPL1 gene .  Furthermore, 
patients at risk of metabolic crisis could be identified. It 
is of note that while GKD and DMD can also be ruled out 
by measuring glycerol, triglycerides and creatine kinase, 
respectively, no markers for MR are available, making the 
detection of  IL1RAPL1 deletions in very young patients 
of significant help for the prognosis of the patient. How-
ever, it is important to remember that a severe adrenal 
crisis due to AHC can lead to brain damage and conse-
quent MR, as well as that GKD can lead to psychomotor 
impairment as a consequence of hypoglycemic episodes 
 [8] . These two latter causes of MR can be prevented with 
optimal medical management. The identification of the 
genetic rearrangement in AHC patients offers not only a 
more accurate genetic counseling to the family but also a 
better management of the patients. It allows the identifi-
cation of a still asymptomatic affected male within the 
family, thus preventing life-threatening adrenal crises. 
Furthermore, the identification and characterization of a 
deletion allows the prevention and early management of 
different symptoms due to the other genes involved in the 
mutation.
 Compared to a PCR approach, MLPA analysis is less 
laborious, as several target genes can be screened in one 
reaction, and it offers the advantage of detecting hetero-
zygous deletions in female subjects, who, depending on 
the extension of the deletion, have a high risk of having 
children with MR, AHC, GKD and DMD. The risk is 
actually 50% for having an affected son and 50% for 
having a carrier daughter. Although the majority of fe-
male carriers of X-linked diseases are asymptomatic, 
some can present symptoms due to skewed X inactiva-
tion. In fact, delayed puberty showed by some female 
carriers of  NR0B1 mutations is postulated to arise due to 
a non-random X inactivation  [20] . Furthermore, a fe-
male with salt-losing AHC, GKD and mild dystrophi-
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nopathy due to skewed X inactivation of the normal X 
chromosome, instead of the X chromosome carrying 
the contiguous gene deletion including  NR0B1 ,  GK and 
part of the  DMD gene, was recently described  [21] . X in-
activation was also shown to be complete on lympho-
cytes and skewed 80: 20% in muscle. DMD female carri-
ers manifesting milder symptoms have also been de-
scribed  [22] . Thus, female carriers of  NR0B1 as well as of 
 GK or  DMD mutations are at risk of developing symp-
toms, due to non-random X inactivation. Furthermore, 
in case of a contiguous gene deletion, the manifestation 
of the symptoms depends on the pattern of X inactiva-
tion in different tissues. All this makes the detection of 
female carriers of deletions even more important. Ar-
ray-based platforms to evaluate copy number changes 
can also be used to identify and narrow down deletion 
extensions; however, the resolution depends on the plat-
form of choice and the location of the probes, as rela-
tively small deletions can escape detection ( NR0B1 is 
only 5 kb). A combination of methods may be especially 
helpful in mapping larger deletions, as shown here for 
index patients 3 and 4. In our assay, the placement of one 
probe on each  NR0B1 exon guarantees the identification 
of deletions affecting only one exon, and the location of 
probes at the very end of the  IL1RAPL1 and  DMD genes 
allow the identification of deletions extending to the 
very end of these genes. A disadvantage of MLPA, com-
mon to the other quantitative methods (i.e. quantitative 
PCR arrays, platforms), is that it cannot identify chro-
mosome rearrangements, such as inversions and trans-
locations that do not affect the copy number but can still 
affect proper gene expression  [23] .
 To conclude, MLPA analysis is a valuable tool to de-
tect  NR0B1 and contiguous gene deletions in patients 
with AHC. The investigation has shown a good geno-
type-phenotype correlation. It is especially helpful for 
the detection of  IL1RAPL1  deletions causing MR. Fur-
thermore, MLPA has the advantage of identifying fe-
male carriers.
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